Negative Allosteric Modulators of A_2AR: A New Weapon for Cancer Immunotherapy?

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Adenosine signaling via A2A receptors (A2A R) promotes immunosuppression in tumor microenvironments (TMEs), hindering anti-cancer immune responses.
• Current A2A R antagonists face challenges including competitive binding and off-target effects, limiting their therapeutic efficacy.

Purpose of the Study:

• To develop novel negative allosteric modulators (NAMs) of A2A R as a potential cancer immunotherapy strategy.
• To evaluate the efficacy of these A2A R NAMs in high-adenosine TMEs.

Main Methods:

• Development of a novel series of A2A R NAMs.
• Assessment of NAM activity in preclinical models simulating high-adenosine TMEs.

Main Results:

• The novel A2A R NAMs demonstrated potent activity in high-adenosine TMEs.
• NAMs exhibit a noncompetitive, saturable mechanism, enhancing receptor selectivity compared to orthosteric antagonists.

Conclusions:

• A2A R NAMs represent a promising therapeutic approach for cancer immunotherapy.
• These findings highlight the translational potential of A2A R NAMs in oncology for enhancing anti-cancer immunity.